Additional file 2 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Goeldner, Celia; Kishnani, Priya S.; Skotko, Brian G.; Casero, Julian Lirio; Hipp, Joerg F.; Derks, Michael; Hernandez, Maria-Clemencia; Khwaja, Omar; Lennon-Chrimes, Sian; Noeldeke, Jana; Pellicer, Sabine; Squassante, Lisa; Visootsak, Jeannie; Wandel, Christoph; Fontoura, Paulo; d’Ardhuy, Xavier Liogier

doi:10.6084/m9.figshare.19129019.v1

11689_2022_9418_MOESM2_ESM.doc (144 kB)

Additional file 2 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

journal contribution

posted on 2022-02-07, 04:30 authored by Celia Goeldner, Priya S. Kishnani, Brian G. Skotko, Julian Lirio Casero, Joerg F. Hipp, Michael Derks, Maria-Clemencia Hernandez, Omar Khwaja, Sian Lennon-Chrimes, Jana Noeldeke, Sabine Pellicer, Lisa Squassante, Jeannie Visootsak, Christoph Wandel, Paulo Fontoura, Xavier Liogier d’Ardhuy

Additional file 2. Study design.

Funding

F. Hoffmann-La Roche

History

Usage metrics

Keywords

Down syndrome GABAA-α5 Cognition Adaptive behavior EEG

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 2 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Funding

F. Hoffmann-La Roche

History

Usage metrics

Categories

Keywords

Licence

Exports